Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma, Inc. - Common Stock (NQ: LUMO )

4.340 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lumos Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
A Preview Of Lumos Pharma's Earnings
Via Benzinga
Lumos Pharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Lumos Pharma Says Growth Hormone Deficiency Trial Meet Expectations
Via Benzinga
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Recap: Lumos Pharma Q2 Earnings
  Lumos Pharma (NASDAQ:LUMO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
From Lumos Pharma, Inc.
Via GlobeNewswire
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 34 companies set new 52-week lows. 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
From Lumos Pharma, Inc.
Via GlobeNewswire
Earnings Outlook For Lumos Pharma
  Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Lumos Pharma... 
Via Benzinga
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
From Lumos Pharma, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Lumos Pharma: Q1 Earnings Insights
Lumos Pharma (NASDAQ:LUMO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lumos Pharma missed estimated... 
Via Benzinga
Lumos Pharma's Earnings: A Preview
Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Lumos Pharma... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.